Abstract
Compared with warfarin in patients with nonvalvular atrial fibrillation, dabigatran at a dose of 150 mg twice daily is more effective for the prevention of stroke and systemic embolism with a similar risk of major bleeding, and at a dose of 110 mg twice daily has similar effectiveness with less major bleeding. The TGA recommends use of the higher dose except in patients aged over 75 years or with a high bleeding risk or with moderate renal impairment, where they suggest the lower dose should be used.
Original language | English |
---|---|
Pages (from-to) | 69-75 |
Number of pages | 7 |
Journal | Medicine Today |
Volume | 14 |
Issue number | 3 |
Publication status | Published - Mar 2013 |